A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024)

• Status: Not yet recruiting
• Trial end date: 2027-03-16
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of belzutifan monotherapy and belzutifan plus palbociclib combination therapy in participants with advanced clear-cell renal cell carcinoma (ccRCC) who experienced disease progression on or after receiving prior therapy. Part 1 will establish the safety of belzutifan plus palbociclib and determine a recommended dosage of palbociclib for the combination therapy by ascending dose escalation. Part 2 will evaluate the efficacy and safety of belzutifan plus palbociclib at the dosage level determined in Part 1.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme LLC
• Treatments: Palbociclib

Criteria

Inclusion Criteria:

• Has a histologically confirmed diagnosis of unresectable Stage IV (per American Joint Committee on Cancer [AJCC], 8th Edition) RCC with clear-cell component

• Has had disease progression on or after having received at least 2 systemic treatments for unresectable Stage IV RCC with prior anti-programmed cell death 1 ligand 1 (PD-1/L1) and a vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) in sequence or in combination

• Has measurable disease per RECIST 1.1 as assessed by the investigator and verified by blinded independent central review (BICR)

• Has recovered from all AEs due to previous therapies

Exclusion Criteria:

• Has hypoxia, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen

• Has a known additional malignancy that is progressing or has required active treatment within the past 3 years

• Has known central nervous system (CNS) metastases and/or carcinomatous meningitis

• Has clinically significant cardiac disease

• Has moderate to severe hepatic impairment

• Has a known history of human immunodeficiency virus (HIV) infection

• Has a history of hepatitis B (HBV) or known active hepatitis C (HCV) infection

• Has received prior treatment of belzutifan or palbociclib

• Has received prior radiotherapy ≤2 weeks prior to first dose of study intervention. Participants must have recovered from all radiation-related toxicities and not require corticosteroids

• Has had major surgery ≤3 weeks prior to first dose of study intervention

• Has received colony-stimulating factors (eg, granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF], or recombinant erythropoietin [EPO]) ≤28 days prior to the first dose of study intervention